Therapy of membranous nephropathy: ?
作者信息
Glassock Richard J
机构信息
Emeritus Professor, Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
出版信息
Clin Kidney J. 2023 Apr 10;16(9):1432-1433. doi: 10.1093/ckj/sfad074. eCollection 2023 Sep.
Abstract
摘要
相似文献
1
Therapy of membranous nephropathy: ?
Clin Kidney J. 2023 Apr 10;16(9):1432-1433. doi: 10.1093/ckj/sfad074. eCollection 2023 Sep.
2
Molecular Characterization of Membranous Nephropathy:
J Am Soc Nephrol. 2022 Jun;33(6):1057-1059. doi: 10.1681/ASN.2022040395. Epub 2022 May 16.
3
Membranous nephropathy: quo vadis?
Kidney Int. 2002 Jan;61(1):349-50. doi: 10.1046/j.1523-1755.2002.00125.x.
4
[Rheumatology-Quo Vadis? Health System-Quo Vadis?].
Rheuma Plus. 2023;22(3):119-121. doi: 10.1007/s12688-023-00620-z. Epub 2023 Jun 2.
5
medycyno regeneracyjna?: Quo Vadis Regenerative Medicine?
Acta Haematol Pol. 2013 Jul;44(3):161-170. doi: 10.1016/j.achaem.2013.07.023.
6
Endothelial (DYS)Function: Quo vadis, Cur vadis.
J Hypertens. 2012 Jul;30(7):1321-4. doi: 10.1097/HJH.0b013e32835522e2.
7
Thoracic Epidural Analgesia for Severe Acute Pancreatitis: Quo Vadis Intensivist?
Indian J Crit Care Med. 2019 Feb;23(2):59-60. doi: 10.5005/jp-journals-10071-23117.
8
Meningioma research-status quo and quo vadis.
Chin Clin Oncol. 2017 Jul;6(Suppl 1):S1. doi: 10.21037/cco.2017.06.21.
9
Membranous Nephropathy: Updates on Management.
Adv Kidney Dis Health. 2024 Jul;31(4):299-308. doi: 10.1053/j.akdh.2024.04.004.
10
Quo venis quo vadis: the evolution of arthroscopy.
Arthroscopy. 1999 Sep;15(6):680-5. doi: 10.1016/s0749-8063(99)00141-3.
本文引用的文献
1
Anti-CD20 should be the first-line treatment in high-risk membranous nephropathy.
Clin Kidney J. 2023 Apr 10;16(9):1420-1425. doi: 10.1093/ckj/sfad075. eCollection 2023 Sep.
2
The place of cyclical therapy for the treatment of membranous nephropathy in the era of rituximab.
Clin Kidney J. 2023 Apr 10;16(9):1426-1431. doi: 10.1093/ckj/sfad081. eCollection 2023 Sep.
3
Antibody-Guided Therapy in Phospholipase A2 Receptor-Associated Membranous Nephropathy.
Kidney Int Rep. 2022 Dec 13;8(3):432-441. doi: 10.1016/j.ekir.2022.12.003. eCollection 2023 Mar.
4
Mapping antigens of membranous nephropathy: almost there.
Kidney Int. 2023 Mar;103(3):469-472. doi: 10.1016/j.kint.2023.01.003.
5
T-cell epitopes of PLA2R1 in membranous nephropathy: another step toward antigen-based immunotherapies.
Kidney Int. 2023 Mar;103(3):466-469. doi: 10.1016/j.kint.2022.12.018.
6
Pathogenicity of Human Anti-PLA 2 R1 Antibodies in Minipigs: A Pilot Study.
J Am Soc Nephrol. 2023 Mar 1;34(3):369-373. doi: 10.1681/ASN.0000000000000068. Epub 2023 Jan 5.
7
Analysis of glomerular PLA2R efficacy in evaluating the prognosis of idiopathic membranous nephropathy in the background of different serum anti-PLA2R levels.
Ren Fail. 2022 Dec;44(1):731-740. doi: 10.1080/0886022X.2022.2068442.
8
Recent Clinical Trials Insights into the Treatment of Primary Membranous Nephropathy.
Drugs. 2022 Feb;82(2):109-132. doi: 10.1007/s40265-021-01656-1. Epub 2021 Dec 21.
9
Membranous nephropathy.
Nat Rev Dis Primers. 2021 Sep 30;7(1):69. doi: 10.1038/s41572-021-00303-z.
10
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases.
Kidney Int. 2021 Oct;100(4S):S1-S276. doi: 10.1016/j.kint.2021.05.021.
Zotero 插件